P587: COVALENT-101: A PHASE 1 STUDY OF BMF-219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, AND MULTIPLE MYELOMA

• F. Ravandi-Kashani,
• A. Kishtagari,
• H. Carraway,
• G. Schiller,
• E. Curran,
• B. Yadav,
• A. Cacovean,
• S. Morris,
• T. Butler,
• J. Lancet

Affiliations

F. Ravandi-Kashani

1 Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston

A. Kishtagari

2 Vanderbilt-Ingram Cancer Center, Nashville

H. Carraway

3 Cleveland Clinic Foundation, Cleveland

G. Schiller

4 University of California Los Angeles, Los Angeles

E. Curran

5 University of Cincinnati Medical Center, Cincinnati

B. Yadav

6 Biomea Fusion, Inc, Redwood City

A. Cacovean

6 Biomea Fusion, Inc, Redwood City

S. Morris

6 Biomea Fusion, Inc, Redwood City

T. Butler

6 Biomea Fusion, Inc, Redwood City

J. Lancet

7 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, United States of America